Table 3

Association of CYP3A4 genotype and clinical characteristics among 103 African-American prostate cancer cases over the age of 65

Clinical characteristicCYP3A4 genotype, n (%)aOR (95% CI)b
AAAGGG
Gleason grade
 ≤715 (19%)35 (44%)30 (37%)
 >73 (13%)7 (30%)13 (57%)2.2 (0.9–5.8)
PSA at diagnosisc
 ≤106 (24%)12 (48%)7 (28%)
 >1011 (14%)30 (39%)36 (47%)2.2 (0.8–5.9)
TNM stage
 T1a–c/T2–b12 (16%)33 (45%)29 (39%)
 T2c/T3/T4/M6 (21%)9 (31%)14 (48%)1.4 (0.6–3.3)
Grade/Staged
 Low11 (17%)31 (49%)21 (33%)
 High7 (17%)11 (28%)22 (55%)2.4 (1.1–5.4)
  • a n, number of subjects. A, wild type; G, variant.

  • b Comparing those with GG versus those with AA and AG genotypes (recessive model). Adjusted for age at diagnosis and family history.

  • c Units for PSA, ng/ml.

  • d Combined Gleason grade and TNM stage is defined as: Low, T1a–T1c or T2a–b stage and Gleason grade ≤7; High, T2c, T3, T4, or M stage and Gleason grade >7. Gleason grading is detailed in Gleason (8) ) and TNM staging in Spiessl (9) ).